KAZIA THERAPEUTICS-SPON ADR (KZIA) Forecast, Price Target & Analyst Ratings

NASDAQ:KZIA • US48669G3039

Current stock price

8.82 USD
-0.28 (-3.08%)
Last:

Analyst forecast overview

View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for KAZIA THERAPEUTICS-SPON ADR (KZIA).

Forecast Snapshot

Consensus Price Target

Price Target
$19.38
+ 119.73% Upside
→ Price target details

Next Earnings Forecast

Earnings Estimate
Release Date
N/A
Period
Q4 / 2026
EPS Estimate
-A$0.72
Revenue Estimate
51K
→ Full earnings forecast details

ChartMill Buy Consensus

Rating
82.50%
Weighted Analyst Rating Score
→ Analyst Ratings details

Price Target Details & History

Consensus Price Target and Range

Mean target
$19.38
Upside
+ 119.73%
From current price of $8.82 to mean target of $19.38, Based on 8 analyst forecasts
Low
$18.18
Median
$19.38
High
$21.00

Price Target Revisions

1 Month
0.00%
3 Months
0.00%

Price Target Summary

8 Wall Street analysts provided a forecast for the next 12 months for KZIA. The average price target is 19.38 USD. This implies a price increase of 119.73% is expected in the next year compared to the current price of 8.82.
→ Find peer stocks trading 30% below analyst price target

Analyst Ratings & History

Current Analyst Ratings

KZIA Current Analyst RatingKZIA Current Analyst Buy, Sell and Hold Ratings.Current Analyst Rating Strong Buy Buy Hold Sell Strong Sell 1 2 3 4

Analyst Ratings History

KZIA Historical Analyst RatingsKZIA Historical Analyst Buy, Sell and Hold Ratings and number of analysts.Historical Monthly Analyst Rating -19 -17 -15 -13 -11 -9 -7 -5 -3 -1 2 4 6

Analyst Ratings Consensus

ChartMill Buy Consensus
82.50%
KZIA was analyzed by 8 analysts. The buy percentage consensus is at 83. So analysts seem to be very confident about KZIA.
In the previous month the buy percentage consensus was at a similar level.
KZIA was analyzed by 8 analysts. More opinions would make the average more meaningful.
→ Find peer stocks with a buy consensus above 85%

Recent Upgrades & Downgrades

DateFirmActionFrom → To
2026-01-28HC Wainwright & Co.Reiterate Buy -> Buy
2025-12-12HC Wainwright & Co.Maintains Buy -> Buy
2025-10-02Maxim GroupMaintains Buy -> Buy
2025-07-10HC Wainwright & Co.Maintains Buy -> Buy
2025-06-11Maxim GroupMaintains Buy -> Buy
2025-02-06Maxim GroupInitiate Buy
2024-07-12HC Wainwright & Co.Reiterate Buy -> Buy
2023-04-11HC Wainwright & Co.Upgrade Neutral -> Buy
2022-08-02Maxim GroupDowngrade Buy -> Hold
2022-08-02HC Wainwright & Co.Downgrade Buy -> Neutral
2021-10-14Maxim GroupInitiate Buy

Next Earnings Forecast Details

Next Earnings Details

Release Date
N/A
Period
Q4 / 2026
EPS Estimate
-A$0.72
Revenue Estimate
51K
Revenue Q2Q
21.43%
EPS Q2Q
-151.00%
Number of Analysts
3

Next Earnings Revisions

Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
N/A
EPS (3 Months)
N/A

Next Earnings Summary

→ Find peers expecting at least 20% revenue growth next quarter

Full Analyst Estimates 2026 - 2033

Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates

2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033
Revenue
YoY % growth
KZIA revenue by date.KZIA revenue by date.
22.6K
976.19%		2.32M
10,165.49%		114K
-95.09%		51K
-55.26%		31.11K
-39.00%		996.03K
3,101.64%		30.41M
2,953.12%		160.36M
427.33%		331.79M
106.90%		505.73M
52.42%		686.33M
35.71%
EBITDA
YoY % growth
KZIA ebitda by date.KZIA ebitda by date.
N/A
-9.90%		N/A
124.14%		N/A
16.50%		N/AN/AN/AN/AN/AN/AN/AN/A
EBIT
YoY % growth
KZIA ebit by date.KZIA ebit by date.
-24.125M
4.95%		-27.193M
-12.72%		-18.201M
33.07%		-23.425M
-28.70%		-24.956M
-6.53%		-27.47M
-10.08%		-4.618M
83.19%		112.52M
2,536.76%		263.2M
133.91%		412.14M
56.59%		564.41M
36.95%
Operating Margin
KZIA operating margin by date.KZIA operating margin by date.
-106,745.58%-1,172.11%-15,965.79%-45,932.00%-80,218.03%-2,757.96%-15.18%70.17%79.33%81.49%82.24%
EPS
YoY % growth
KZIA eps by date.KZIA eps by date.
N/A
89.43%		N/A
100.20%		N/A
-30,372.73%		-0.69
79.58%		-0.57
18.38%		-0.54
5.41%		0.00
100.25%		0.08
5,992.31%		0.17
104.80%		0.26
56.91%		0.36
39.88%

All data in AUD

Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates

Q4 / 26
EPS
Q2Q % growth		-0.72
-151.00%
Revenue
Q2Q % growth		51K
21.43%
EBITDA
Q2Q % growth		N/A
EBIT
Q2Q % growth		-12.596M
-78.71%

All data in AUD

Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data

KZIA Yearly Revenue VS EstimatesKZIA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 200M 400M 600M
KZIA Yearly EPS VS EstimatesKZIA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 -50 -100

Long Term Forward Growth Forecast Summary

Long Term EPS Growth (CAGR)

EPS Next 3 Year
22.59%
EPS Next 5 Year
15.14%

Long Term Revenue Growth (CAGR)

Revenue Next 3 Year
144.27%
Revenue Next 5 Year
372.16%

Long Term EBIT Growth (CAGR)

EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A
→ Find peers expecting at least 20% CAGR revenue growth over the next 3 years

KAZIA THERAPEUTICS-SPON ADR / KZIA Forecast FAQ

Can you provide the average price target for KAZIA THERAPEUTICS-SPON ADR stock?

8 analysts have analysed KZIA and the average price target is 19.38 USD. This implies a price increase of 119.73% is expected in the next year compared to the current price of 8.82.

Can you provide the consensus estimates for KAZIA THERAPEUTICS-SPON ADR next earnings?

The consensus EPS estimate for the next earnings of KAZIA THERAPEUTICS-SPON ADR (KZIA) is -0.72 USD and the consensus revenue estimate is 51.00K USD.

What is the expected long term growth rate for KAZIA THERAPEUTICS-SPON ADR (KZIA)?

The expected long term growth rate for KAZIA THERAPEUTICS-SPON ADR (KZIA) is 144.27%.